TYGlobe

How do mechanisms including the Drug‑Patent Linkage System, the Bolar Exception and Patent Term Compensation reshape the competitive landscape between originator‑drug enterprises and generic‑drug manufacturers? Drawing on the latest judicial precedents, this article conducts an in‑depth analysis of core legal issues in pharmaceutical patent law.

I. Institutional Framework for Pharmaceutical Patent Protection

China’s pharmaceutical‑patent protection regime has evolved from scratch, growing from rudimentary to sophisticated. It has transitioned from a simple model of “patent grant plus infringement remedies” into a composite institutional framework: basic patent protection + patent‑term compensation + drug‑patent linkage mechanism + data protection + balance between compulsory licensing and the Bolar Exception. This framework seeks a dynamic balance between incentivizing originator‑drug innovation and improving generic‑drug accessibility.

1. Basic Patent Regime

The Patent Law of the People’s Republic of China and its implementing regulations constitute the cornerstone of pharmaceutical patent protection. While applying the same general patent rules as other technical fields, it contains special provisions for pharmaceuticals:

Patent‑eligible subject‑matter: Product patents for pharmaceuticals (compounds, compositions, formulations), process patents (preparation processes, quality‑control methods), and use patents (new indications, new administration routes) are all eligible for protection.

Grant requirements: Inventions must satisfy novelty, inventive step and practical applicability.

Term of protection: Invention‑patent protection lasts 20 years from the filing date.

Bolar Exception: Manufacturing, using or importing patented pharmaceuticals or medical devices for the purpose of generating information required for administrative approval for drug registration shall not be deemed patent infringement (Article 75 of the Patent Law). This mechanism strikes a balance between generic‑drug marketing approval and patent protection.

2. Pharmaceutical Patent‑Term Compensation System (PTE)

Introduced in the fourth amendment to the Patent Law in 2020, it offsets time consumed by drug review‑and‑approval procedures:

Applicable subjects: Invention patents relating to new drugs that have obtained marketing authorization in China.

Compensation term: Compensation shall not exceed five years. The total valid patent‑protection term after new‑drug marketing approval shall not exceed 14 years.

Function: Compensates for the shortened effective patent term caused by lengthy clinical trials and administrative review, so as to incentivize originator‑drug innovation.

3. Early‑Resolution Mechanism for Pharmaceutical Patent Disputes (Drug‑Patent Linkage System)

Established under the Measures for the Implementation of the Early‑Resolution Mechanism for Pharmaceutical Patent Disputes (Trial) of 2021, it provides procedural connection between drug registration review and patent protection.

Patent‑information registration: The Catalog of Marketed Drugs (China Marketed‑Drug Patent Information Registration Platform) records patent information for marketed pharmaceutical products.

Patent‑declaration system: Generic‑drug applicants must submit one of four categories of patent declarations when filing marketing applications (Categories I‑IV, analogous to US Paragraph IV certifications).

Dispute‑resolution procedures: A nine‑month waiting period applies to chemical drugs, during which patent holders or interested parties may file civil lawsuits or request administrative rulings. Separate rules govern biological products and traditional Chinese medicines.

Market exclusivity for first‑filed generics: A 12‑month market‑exclusivity period is granted for the first successful patent‑challenging chemical generic drug to obtain marketing approval.

4. Pharmaceutical Test‑Data Protection System

Though not formally part of patent law, it complements patent‑right protection:

Protected subject‑matter: Registration‑application data for drugs containing new‑chemical entities, data for biological products first filed in China, etc.

Protection duration: Six years for innovative drugs; three years in certain cases for improved new drugs; extensions may apply for orphan‑drug therapies, pediatric medicines, innovative vaccines and other products.

Function: Prevents generic‑drug companies from directly relying on clinical‑trial data generated by originator firms to file for marketing approval after patent expiry, thereby creating “data exclusivity” protection.

5. Law‑enforcement and Remedy Regime

Judicial protection: Civil litigation for patent infringement, including pre‑litigation injunctions, damages, and punitive damages (1‑5 times the compensatory award for intentional and serious infringement).

Administrative protection: Patent‑administrative authorities may handle infringement disputes and order cessation of infringing acts.

Compulsory licensing: Under states of national emergency, extraordinary circumstances or in furtherance of the public interest, the competent patent‑administrative department of the State Council may grant compulsory licences for invention‑patent exploitation (Chapter VI of the Patent Law). Compulsory licensing remains extremely rare in pharmaceutical practice.

6. Alignment between international treaties and domestic law

TRIPS Agreement: The Agreement on Trade‑Related Aspects of Intellectual‑Property Rights sets minimum‑protection standards binding on China as a WTO Member.

RCEP, CPTPP and other regional agreements: Regional trade agreements ratified by China contain pharmaceutical‑intellectual‑property clauses that exert influence on domestic institutions.

These interrelated and mutually‑restraining rules form a sophisticated balancing mechanism.

II. Core Controversies in Drug‑Patent Linkage Litigation

The 2026 first‑instance judgment of the Beijing Intellectual‑Property Court in the dispute between AstraZeneca and a generic‑drug enterprise delivers key judicial guidance on three central controversies arising under the drug‑patent linkage system.

Case Background

In a drug‑patent‑linkage proceeding, a generic‑drug enterprise filed a Category 4.2 declaration asserting that its technical solution did not fall within the scope of patent protection. AstraZeneca subsequently initiated litigation. During proceedings, the generic‑drug firm promised it would not seek marketing approval for its generic product while the patent remained in force and amended its filing to a Category 3 declaration (undertaking not to launch before patent expiry). Reliant on this undertaking, AstraZeneca withdrew its suit. Later, the generic drug obtained marketing authorization, was listed on multiple drug‑procurement platforms and achieved actual sales in several regions. AstraZeneca brought a new action for patent infringement.

Controversy 1: Binding effect of the “non‑launch‑for‑the‑time‑being” undertakingIs a generic‑drug enterprise’s “non‑launch‑for‑the‑time‑being” undertaking in patent‑linkage litigation legally binding? The court held clearly: once an undertaking secures withdrawal of the opposing party’s lawsuit, it cannot be freely repudiated in subsequent procedures. This follows the principle of good faith and preserves institutional credibility for the entire drug‑patent‑linkage regime.

Controversy 2: Assessment standard for design‑aroundMay generic‑drug firms avoid patent coverage merely by adjusting partial technical parameters? Instead of evaluating final numerical values in isolation, the court focused on the essence of the technical solution. A valid design‑around must embody substantive technical modification rather than superficial adjustment of calculation metrics.

Controversy 3: Does platform listing constitute “offer for sale”?The court ruled that successful listing on provincial‑municipal procurement platforms with active transaction status sends a clear supply signal to the market and goes beyond mere preparatory acts for marketing.

III. Compliance Strategies for Generic‑Drug Enterprises

While generic‑drug enterprises may legitimately deploy the Bolar Exception and patent‑challenge mechanisms, material risks must be managed:

Patent declarations shall be truthful and accurate. Category 4.2 non‑infringement declarations must rest on thorough technical analysis and legal assessment and cannot amount to tactical procedural manoeuvres.

Timing of market launch is critical. Premature commercial activities pending unresolved patent litigation may be deemed intentional infringement triggering punitive damages.

Design‑around measures demand deep collaboration between legal and technical teams. Strategies seeking formal non‑infringement solely by tweaking parameters or excipients carry substantial risk.

IV. Development Trends in Pharmaceutical‑Patent Institutions

What do these shifts mean for pharmaceutical market participants? First, compliance cannot remain merely paper‑based. Enterprises must build closed‑loop systems covering organizational structures, internal workflows, staff training and internal audits. Second, legal‑risk assessment shall be brought forward in commercial decision‑making, especially for drug access, marketing‑promotion and pricing strategies. Third, permanent regulatory‑update tracking mechanisms should be established to capture policy shifts and implement timely adjustments.

V. Debates and Outlook

Notwithstanding an increasingly complete statutory framework, multiple open‑debate points persist. How can policymakers strike an optimal balance between fostering innovation and guaranteeing drug accessibility? Are institutional designs for patent protection and generic‑drug competition sufficiently refined? These questions are both legal‑interpretation challenges and public‑policy concerns deserving sustained attention.

The core logic of pharmaceutical‑patent systems lies in balance: protecting innovation to incentivize R&D while reserving reasonable market space for generic‑drug competition. Mastery and prudent application of these rules constitute a prerequisite for sustained competitiveness for both originator‑drug and generic‑drug enterprises.

Drawing on typical drug‑patent‑linkage cases, this article analyses patent‑risk‑assessment strategies for generic‑drug enterprises during marketing‑application procedures. As the timeless tension between patent protection and pharmaceutical accessibility plays out under updated institutional frameworks, legal professionals assume an increasingly pivotal role.